The Swiss pharmaceutical giant's plant will produce compounds needed for radioligand therapy (RLT), a form of precision ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

By Patrick Wingrove (Reuters) -Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in ...

Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet ...

Novartis plans to acquire Avidity Biosciences to add RNA therapeutics to its neuroscience biz to target rare genetic ...

Novartis invests $23B in U.S. infrastructure, opening a new Carlsbad facility and expanding radioligand therapy sites. Read ...

Novartis, a global innovative medicines company, has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, CA.

Secondary endpoints “indicate symptom reduction and patient benefit beyond improvement in disease activity,” according to ...

Novartis AG is nearing a deal to buy biotechnology company Avidity Biosciences Inc., according to a person familiar with the matter.

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter, dragging the Swiss company's shares lower, as its top-selling drug comes under pressure from cheaper ...

Swiss drugmaker Novartis is exploring options to add more medicines to its direct-to-patient platform that is expected to ...